Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution
Accuray Incorporated (NASDAQ: ARAY) announced that Gifu Prefectural General Medical Center in Japan has become the first hospital in the country to treat cancer patients using the Radixact® Radiation Delivery System and VitalHold™ solution for surface-guided radiation therapy (SGRT). This technology enables precise patient positioning and monitoring during treatment, including the deep inspiration breath hold (DIBH) technique for left breast cancer.
The hospital's adoption of this technology is part of its plan to expand patient access to high-precision radiation therapy. Dr. Yuichi Kajiura, from the department of radiation oncology, highlighted the benefits of the Radixact System with VitalHold, including faster patient setup and improved monitoring throughout treatment. The hospital is also using ClearRT™ to produce diagnostic-like quality images for more informed treatment decisions.
Accuray Incorporated (NASDAQ: ARAY) ha annunciato che il Gifu Prefectural General Medical Center in Giappone è diventato il primo ospedale del paese a trattare pazienti affetti da cancro utilizzando il sistema di erogazione di radiazioni Radixact® e la soluzione VitalHold™ per la terapia con radiazioni guida superficie (SGRT). Questa tecnologia consente un posizionamento e un monitoraggio precisi del paziente durante il trattamento, inclusa la tecnica di apnea profonda (DIBH) per il cancro al seno sinistro.
L'adozione di questa tecnologia da parte dell'ospedale fa parte del suo piano per espandere l'accesso dei pazienti alla radioterapia ad alta precisione. Il Dr. Yuichi Kajiura, del dipartimento di oncologia radioterapica, ha sottolineato i benefici del sistema Radixact con VitalHold, tra cui un'impostazione del paziente più rapida e un monitoraggio migliorato durante tutto il trattamento. L'ospedale sta anche utilizzando ClearRT™ per produrre immagini di qualità diagnostica per decisioni di trattamento più informate.
Accuray Incorporated (NASDAQ: ARAY) anunció que el Gifu Prefectural General Medical Center en Japón se ha convertido en el primer hospital del país en tratar a pacientes con cáncer utilizando el Radixact® Radiation Delivery System y la solución VitalHold™ para la terapia de radiación guiada por superficie (SGRT). Esta tecnología permite un posicionamiento y monitoreo precisos del paciente durante el tratamiento, incluida la técnica de retención de la respiración en inspiración profunda (DIBH) para el cáncer de mama izquierdo.
La adopción de esta tecnología por parte del hospital es parte de su plan para ampliar el acceso de los pacientes a la radioterapia de alta precisión. El Dr. Yuichi Kajiura, del departamento de oncología radioterápica, destacó los beneficios del sistema Radixact con VitalHold, que incluyen una configuración del paciente más rápida y un mejor monitoreo durante todo el tratamiento. El hospital también está utilizando ClearRT™ para producir imágenes de calidad diagnóstica para decisiones de tratamiento más informadas.
Accuray Incorporated (NASDAQ: ARAY)는 일본의 기후현 종합 의료 센터가 Radixact® 방사선 제공 시스템과 표면 유도 방사선 치료(SGRT)를 위한 VitalHold™ 솔루션을 사용하여 암 환자를 치료하는 일본 최초의 병원이 되었다고 발표했습니다. 이 기술은 치료 중 환자의 정확한 위치 결정과 모니터링을 가능하게 하며, 좌측 유방암을 위한 깊은 호흡 유지(DIBH) 기술이 포함됩니다.
병원의 이 기술 채택은 고정밀 방사선 치료에 대한 환자의 접근을 확대하기 위한 계획의 일환입니다. 방사선 종양학과의 유이치 카지우라 박사는 VitalHold와 함께 사용하는 Radixact 시스템의 장점으로 더 빠른 환자 설정과 치료 전반에 걸친 개선된 모니터링을 강조했습니다. 병원은 또한 보다 정보에 기반한 치료 결정을 위해 진단 품질의 이미지를 생성하기 위해 ClearRT™를 사용하고 있습니다.
Accuray Incorporated (NASDAQ: ARAY) a annoncé que le Gifu Prefectural General Medical Center au Japon est devenu le premier hôpital du pays à traiter des patients atteints de cancer en utilisant le Radixact® Radiation Delivery System et la solution VitalHold™ pour la thérapie par radiation guidée par surface (SGRT). Cette technologie permet un positionnement et un suivi précis du patient pendant le traitement, y compris la technique de maintien de la respiration profonde (DIBH) pour le cancer du sein gauche.
L'adoption de cette technologie par l'hôpital fait partie de son plan pour élargir l'accès des patients à une radiothérapie de haute précision. Le Dr Yuichi Kajiura, du département d'oncologie radiothérapique, a souligné les avantages du système Radixact avec VitalHold, notamment une configuration plus rapide du patient et un suivi amélioré tout au long du traitement. L'hôpital utilise également ClearRT™ pour produire des images de qualité diagnostique pour des décisions de traitement mieux informées.
Accuray Incorporated (NASDAQ: ARAY) gab bekannt, dass das Gifu Präfektur Allgemeinkrankenhaus in Japan das erste Krankenhaus des Landes geworden ist, das Krebspatienten mit dem Radixact® Radiation Delivery System und der VitalHold™ Lösung für die oberflächengeführte Strahlentherapie (SGRT) behandelt. Diese Technologie ermöglicht eine präzise Positionierung und Überwachung des Patienten während der Behandlung, einschließlich der Technik der tiefen Inspirationsberuhigung (DIBH) bei Brustkrebs links.
Die Einführung dieser Technologie durch das Krankenhaus ist Teil seines Plans, den Zugang der Patienten zur hochpräzisen Strahlentherapie auszubauen. Dr. Yuichi Kajiura aus der Abteilung für Strahlentherapie hob die Vorteile des Radixact-Systems mit VitalHold hervor, darunter eine schnellere Patienteneinstellung und eine verbesserte Überwachung während der gesamten Behandlung. Das Krankenhaus nutzt auch ClearRT™, um bilderdiagnoseter Qualität zu erzeugen, um fundiertere Behandlungsentscheidungen zu treffen.
- First hospital in Japan to use Radixact® System and VitalHold™ for SGRT
- Technology enables precise patient positioning and monitoring during treatment
- Faster patient setup and improved treatment accuracy reported by hospital
- ClearRT™ provides diagnostic-like quality images for better treatment planning
- None.
Insights
The introduction of Accuray's Radixact® System with VitalHold™ at Gifu Prefectural General Medical Center marks a significant advancement in radiation therapy in Japan. This technology's ability to provide real-time patient positioning and monitoring could potentially improve treatment precision and outcomes, particularly for challenging cases like left breast cancer.
The adoption of surface-guided radiation therapy (SGRT) represents a shift towards more personalized and adaptive treatment approaches. This could lead to reduced side effects and improved quality of life for patients. However, the true clinical impact and cost-effectiveness of this technology will need to be evaluated over time through real-world data and comparative studies.
For Accuray, this milestone could strengthen its market position in Japan and potentially lead to increased adoption of its technology in other medical centers. Investors should monitor future installations and clinical outcomes to gauge the long-term impact on Accuray's revenue and market share in the competitive radiation therapy market.
While this news is positive for Accuray (NASDAQ: ARAY), its financial impact may be in the short term. The installation at Gifu Prefectural General Medical Center is a single-site implementation and widespread adoption will take time. However, it could serve as a valuable reference site for future sales in Japan, potentially accelerating market penetration.
Investors should focus on future order book growth and revenue recognition patterns related to this technology. The high-value nature of radiation therapy systems means that even a modest increase in installations could significantly impact Accuray's financials. Key metrics to watch include order backlog, system revenue and service revenue growth in upcoming quarters.
It's worth noting that Accuray is currently operating under an interim CEO, which adds some uncertainty to the company's strategic direction. The success of innovations like VitalHold could play a important role in attracting top talent for permanent leadership positions.
The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments
During treatment with SGRT, high resolution cameras continuously monitor a patient's breathing and position in real-time to create a 3-dimensional map of a patient's skin. The image enables medical care teams to easily visualize the difference between the current body position and the target position, helping to ensure the patient is appropriately positioned when radiation is delivered.
"I am very pleased with the customer interest in
Approximately 50 percent of all cancer patients need radiotherapy at least once to cure their cancer, increase the chance of cure or relieve symptoms caused by cancer1. The Gifu Prefectural General Medical Center team is focused on driving a fundamental change in the way cancer is managed.
"We are delighted to announce the commencement of our hospital's use of the Radixact System with VitalHold. In our efforts to enhance the availability of radiation therapy delivered in our department, which has long been a challenge, we have constructed a new building, introduced the Radixact System and will initiate treatments with the Accuray CyberKnife® S7™ System at a later date. One of the reasons we decided to switch from an older C-arm linear accelerator, which we have been using for many years, to the Radixact System, is to take advantage of the unique benefits of helical imaging and delivery in combination with the capabilities of VitalHold," said Yuichi Kajiura, M.D., department of radiation oncology, Gifu Prefectural General Medical Center.
Continued Dr. Kajiura, "By using VitalHold, we can set up patients faster than initially anticipated and monitor the patient's position throughout the radiation treatment. With the use of hypofractionation, or the delivery of increased dose per session, monitoring the patient's position during irradiation has become extremely important. These factors enable us to deliver highly accurate treatments and will help us to provide the highest quality medical services to our patients."
At Gifu Prefectural General Medical Center, the team is using ClearRT™ to produce diagnostic-like quality images that will empower them to make more informed decisions about all aspects of their patients' treatments. To date, ClearRT has facilitated accurate patient alignment - with clearer images - than conventional MVCT. ClearRT has also enabled the Gifu team to plan and deliver more precise treatments, by providing them with the ability to clearly see changes in the contours of the body and the shape of the tumor due to daily radiation therapy.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations regarding the company's products and upgrades; expectations regarding patient access and cancer management in
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
*VitalHold availability is subject to regulatory clearance or approval in some markets.
1 INTERNATIONAL ATOMIC ENERGY AGENCY, Radiotherapy in Cancer Care: Facing the Global Challenge, Non-serial Publications , IAEA,
View original content to download multimedia:https://www.prnewswire.com/news-releases/gifu-prefectural-general-medical-center-achieves-milestone-with-treatment-of-the-first-cancer-patients-in-japan-using-the-accuray-radixact-system-and-vitalhold-solution-302243466.html
SOURCE Accuray Incorporated
FAQ
What new cancer treatment technology has Gifu Prefectural General Medical Center introduced?
How does the VitalHold™ technology benefit cancer patients?
What imaging technology is Gifu Prefectural General Medical Center using with the Radixact® System?
How has the Radixact® System with VitalHold™ improved treatment at Gifu Prefectural General Medical Center?
